Since July 2023, psilocybin and MDMA-assisted therapy have been available in Australia as part of the Therapeutic Goods Administration’s (TGA’s) Authorised Prescriber (AP) program.

Psychiatrists who have completed specialist training in psychedelic-assisted therapy can apply to become an AP. Access is limited to treatment-resistant depression (psilocybin) and PTSD (MDMA).

On March 7th 2025, The Palliative Care Psychedelic-Assisted Therapy Coalition (the coalition) submitted an application to amend the regulations, to allow psilocybin to also be prescribed for those diagnosed with a terminal illness who are suffering from existential distress.

The application has an upcoming public consultation period (in April & May), and an interim decision will be announced in September. A second public consultation period will take place after the interim decision is announced, before a final decision is made.

Below you can read our application to allow access to psilocybin for those suffering from existential distress towards the end of their lives.